Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences and other industries, was featured on a recent episode of The Stock Day Podcast. PBI’s president and CEO, Richard T. Schumacher, joined Stock Day host Everett Jolly and offered a detailed update of measurable progress the company has made recently in multiple key areas. “Pressure has wonderful, very controllable properties. Unfortunately, scientists really have not had easy access to using pressure safely, especially high pressure, until we came along,” Schumacher said during the program. “We are developing three commercial technology platforms based on our 26 patents. The first one is called Pressure Cycling Technology (‘PCT’), the second is called BaroFold and the third is called Ultra Shear Technology (‘UST’). With PCT, we put the samples to be studied (like bacteria, viruses, cancer cells) in test tubes. We then place the tubes into a pressure chamber of one of our instruments. We need to determine the amount pressure we need to reach, how long it needs to be under that pressure, and how many times we want to cycle the pressure — that is, turn the pressure on and off — in order to open up the pathogen/cancer cell to release the important proteins and nucleic acids contained within, to be studied. This type of elegant control can’t be done nearly as well with heat processing — with heat, you basically get what you get when heating is done. Interestingly, every biological substance in nature has its own unique pressure point, and once you determine that pressure point, you can process that substance (pathogen, cell, enzyme, etc.) right up to the point where it will give you the best results, each and every time. Again, this is very hard to do with temperature and chemicals.”
To view the full press release, visit https://ibn.fm/JxWNt
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
